WallStreetZenWallStreetZen

NASDAQ: RETA
Reata Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for RETA

Based on 7 analysts offering 12 month price targets for Reata Pharmaceuticals Inc.
Min Forecast
$27.00-31.85%
Avg Forecast
$56.29+42.06%
Max Forecast
$115.00+190.26%

Should I buy or sell RETA stock?

Based on 7 analysts offering ratings for Reata Pharmaceuticals Inc.
Buy
Strong Buy
4 analysts 57.14%
Buy
0 analysts 0%
Hold
3 analysts 42.86%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RETA stock forecasts and price targets.

RETA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Goldman Sachs
Top 2%
99
Strong BuyMaintains$115.00+190.26%2022-11-28
Citigroup
Bottom 4%
4
Strong BuyMaintains$53.00+33.77%2022-11-09
Barclays
Bottom 13%
13
Strong BuyMaintains$50.00+26.20%2022-11-09
Guggenheim
Bottom 7%
7
Strong BuyInitiates Coverage On$75.00+89.30%2022-10-19
Baird
Bottom 20%
20
HoldMaintains$27.00-31.85%2022-08-09
Anonymous
Goldman Sachs
HoldMaintains$34.00-14.18%2022-03-01
Goldman Sachs
Top 6%
95
HoldDowngrades$39.00-1.56%2021-12-09
SVB Leerink
Bottom 4%
4
HoldDowngrades$35.00-11.66%2021-12-09

1 of 1

Forecast return on equity

Is RETA forecast to generate an efficient return?
Company
-4,892.85%
Industry
14.42%
Market
62.81%
RETA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RETA forecast to generate an efficient return on assets?
Company
-37.86%
Industry
13.43%
RETA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RETA earnings per share forecast

What is RETA's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$8.37
Avg 2 year Forecast
-$8.31
Avg 3 year Forecast
-$5.49

RETA revenue forecast

What is RETA's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$4.0M+28.29%
Avg 2 year Forecast
$48.0M+1,424.17%
Avg 3 year Forecast
$114.7M+3,541.47%
RETA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RETA revenue growth forecast

How is RETA forecast to perform vs Biotechnology companies and vs the US market?
Company
226.33%
Industry
25.1%
Market
6.74%
RETA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RETA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RETA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RETA$39.62$56.29+42.06%Buy
KDNY$22.77$35.33+55.17%Strong Buy
CVAC$7.60$27.00+255.26%Hold
RCKT$19.03$52.10+173.78%Strong Buy
SWTX$24.25$59.50+145.36%Strong Buy

Reata Pharmaceuticals Stock Forecast FAQ

Is Reata Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: RETA) stock is to Buy RETA stock.

Out of 7 analysts, 4 (57.14%) are recommending RETA as a Strong Buy, 0 (0%) are recommending RETA as a Buy, 3 (42.86%) are recommending RETA as a Hold, 0 (0%) are recommending RETA as a Sell, and 0 (0%) are recommending RETA as a Strong Sell.

If you're new to stock investing, here's how to buy Reata Pharmaceuticals stock.

What is RETA's earnings growth forecast for 2022-2024?

(NASDAQ: RETA) Reata Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.01%.

Reata Pharmaceuticals's earnings in 2022 is -$311,784,000.On average, 4 Wall Street analysts forecast RETA's earnings for 2022 to be -$306,707,392, with the lowest RETA earnings forecast at -$311,837,504, and the highest RETA earnings forecast at -$299,745,098. On average, 4 Wall Street analysts forecast RETA's earnings for 2023 to be -$304,508,773, with the lowest RETA earnings forecast at -$391,720,672, and the highest RETA earnings forecast at -$241,848,123.

In 2024, RETA is forecast to generate -$201,173,666 in earnings, with the lowest earnings forecast at -$270,430,174 and the highest earnings forecast at -$132,283,595.

What is RETA's revenue growth forecast for 2022-2024?

(NASDAQ: RETA) Reata Pharmaceuticals's forecast annual revenue growth rate of 226.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 25.1%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 6.74%.

Reata Pharmaceuticals's revenue in 2022 is $3,149,000.On average, 3 Wall Street analysts forecast RETA's revenue for 2022 to be $148,040,366, with the lowest RETA revenue forecast at $62,294,214, and the highest RETA revenue forecast at $207,769,524. On average, 3 Wall Street analysts forecast RETA's revenue for 2023 to be $1,758,748,865, with the lowest RETA revenue forecast at $1,083,552,878, and the highest RETA revenue forecast at $3,074,402,655.

In 2024, RETA is forecast to generate $4,201,927,919 in revenue, with the lowest revenue forecast at $3,327,243,874 and the highest revenue forecast at $5,076,611,964.

What is RETA's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: RETA) forecast ROA is -37.86%, which is lower than the forecast US Biotechnology industry average of 13.43%.

What is RETA's Price Target?

According to 7 Wall Street analysts that have issued a 1 year RETA price target, the average RETA price target is $56.29, with the highest RETA stock price forecast at $115.00 and the lowest RETA stock price forecast at $27.00.

On average, Wall Street analysts predict that Reata Pharmaceuticals's share price could reach $56.29 by Nov 28, 2023. The average Reata Pharmaceuticals stock price prediction forecasts a potential upside of 42.06% from the current RETA share price of $39.62.

What is RETA's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: RETA) Reata Pharmaceuticals's current Earnings Per Share (EPS) is -$8.56. On average, analysts forecast that RETA's EPS will be -$8.37 for 2022, with the lowest EPS forecast at -$8.51, and the highest EPS forecast at -$8.18. On average, analysts forecast that RETA's EPS will be -$8.31 for 2023, with the lowest EPS forecast at -$10.69, and the highest EPS forecast at -$6.60. In 2024, RETA's EPS is forecast to hit -$5.49 (min: -$7.38, max: -$3.61).

What is RETA's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: RETA) forecast ROE is -4,892.85%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.